Affy Plans to Expand Genetic Analysis Footprint via M&A; May Look Beyond Arrays | GenomeWeb
NEW YORK (GenomeWeb News) – Affymetrix is planning to expand its presence in the genetic analysis market through an “aggressive” merger-and-acquisitions strategy that will likely extend beyond the firm’s foothold in the microarray sector, company officials said recently.
 
Speaking to investors at the recent Baird Growth Stock Conference in Chicago, Affy CFO John Batty said that the company is seeking to “acquire technology that will allow us to compete in the broader genetic-analysis market.”
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.